Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Why Pharvaris (NASDAQ: PHVS) Deucrictibant Could Capture Significant HAE Market Share

The Hereditary Angioedema Market and Deucrictibant's Commercial Opportunity

Nitish Kishor | 07 July 2026

Why TG Therapeutics' (NASDAQ: TGTX) Schizophrenia Bet Could Transform the Company's Valuation

Schizophrenia: The Commercial Opportunity If the Hypothesis Is Correct

Nitish Kishor | 07 July 2026

Why PALSONIFY From Crinetics (NASDAQ: CRNX) Became a $10 Billion Asset

Acromegaly: A High-Value Rare Disease With an Established Treatment Paradigm

Nitish Kishor | 07 July 2026

Why Can-Fite (NASDAQ: CANF) Piclidenoson Q4 2026 Data Is a Market-Moving Event

The Psoriasis Market and Why Differentiation Still Matters

Nitish Kishor | 07 July 2026

Why Atumelnant (Crinetics CRNX) Could Redefine Congenital Adrenal Hyperplasia Treatment

Understanding Congenital Adrenal Hyperplasia and Its Treatment Challenges

Nitish Kishor | 07 July 2026

Why Cosmos Health (NASDAQ: COSM) Is Using a Buyback to Signal Undervaluation

The Strategic Logic of Buybacks in Micro-Cap Healthcare

Nitish Kishor | 07 July 2026

Why Aurinia Pharmaceuticals (NASDAQ: AUPH) Commenced a LUPKYNIS Phase 4 Trial

Lupus Nephritis and LUPKYNIS's Commercial Position

Nitish Kishor | 07 July 2026
Support

Hi! How can we help you today?

Loading…